A Study of LY3540378 in Healthy Participants

Healthy Clinical Trial

Official title:

A Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY3540378 in Healthy Participants

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04768855
• Other study ID #: 17793
• Secondary ID: J3E-MC-EZDA
• Status: Completed
• Phase: Phase 1
• Start date: March 17, 2021
• Est. completion date: May 30, 2022

Study information

• Verified date: June 9, 2022
• Source: Eli Lilly and Company
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The main purpose of this study is to evaluate the safety and tolerability of the study drug known as LY3540378 in healthy participants following single and multiple doses (Parts A and B) and multiple doses in Japanese (Part C) and Chinese (Part D) healthy participants. Blood tests will be performed to check how much LY3540378 gets into the bloodstream and how long it takes the body to eliminate it. This is a 4-part study and may last up to 70, 113, 113 and 113 days for each participant in Parts A, B, C, and D respectively.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 134
• Est. completion date: May 30, 2022
• Est. primary completion date: May 30, 2022
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 21 Years to 65 Years

Eligibility

Inclusion Criteria:

• Overtly healthy males or females, as determined by medical history and physical examination.

• Body mass index (BMI) within the range of 19 to 30 kilograms per meter squared (kg/m²)

• For Part C, participants should be first generation Japanese origin.

• For Part D, participants should be first generation Chinese origin.

• Male participants must agree to adhere to contraception restrictions and female participants not of childbearing potential and may include who are infertile due to surgical sterilization (hysterectomy, bilateral oophorectomy, or tubal ligation), or congenital anomaly such as müllerian agenesis or postmenopausal

Exclusion Criteria:

• Participants with troponin I results above the upper reference limit judged to be clinically significant by the investigator

• Diagnosed with orthostatic hypotension defined as a decrease in systolic blood pressure of 20 mm Hg or a decrease in diastolic blood pressure of 10 mm Hg within 3 minutes of standing when compared with blood pressure from the sitting or supine position.

• Have a significant history of or current cardiovascular (for example, myocardial infarction, congestive HF, cerebrovascular accident, venous thromboembolism, etc.), respiratory, renal, gastrointestinal, endocrine, haematological (including history of thrombocytopenia), or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs

• Have obvious clinical signs or symptoms of liver disease, acute or chronic hepatitis biliary and pancreatic disorder

• Have evidence of significant active neuropsychiatric disease as determined by the investigator

• Have received chronic (lasting >14 consecutive days) systemic glucocorticoid therapy in the past year, or have received any glucocorticoid therapy within 1 month before screening

• Have an abnormality in the 12-lead ECG

• Have serum aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >2 × the upper limit of normal (ULN) or total bilirubin (TBL) >1.5 × ULN

• Have a history of acute or chronic pancreatitis or elevation in serum lipase and/or amylase greater than 1.5 × ULN

• Have known allergies to LY3540378 or related compounds

• Have donated blood of >450 mL, or have participated in a clinical study that required similar blood volume drawn within the past 30 calendar days

• Have an average weekly alcohol intake that exceeds 7 units per week, or are unwilling to stop alcohol consumption as required during the study (1 unit = 12 oz or 360 mL of beer; 5 oz or 150 mL of wine; 1.5 oz or 45 mL of distilled spirits)

• Smoke >10 cigarettes per day or the equivalent, or are unable or unwilling to refrain from nicotine

• Allergy to iodine (shellfish allergy)

• Have a history of sensitivity to lithium carbonate

Related Conditions & MeSH terms

• Healthy

Intervention

Drug:
• LY3540378
Administered IV or SC.
• Placebo
Administered IV or SC.
• LY3540378
Administered SC.

Locations

Country	Name	City	State
Singapore	Lilly Centre for Clinical Pharmacology	Singapore
United States	Anaheim Clinical Trials, LLC	Anaheim	California

Sponsors (1)

Lead Sponsor	Collaborator
Eli Lilly and Company

Countries where clinical trial is conducted

United States,  Singapore, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration	A summary of SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module	Baseline up to Day 113
Secondary	Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY3540378	PK: Cmax of LY3540378	Predose on Day 1 through Day 113
Secondary	PK: Area Under the Concentration Versus Time Curve (AUC) of LY3540378	PK: AUC of LY3540378	Predose on Day 1 through Day 113